Sioux Falls, SDNCT07527858Now EnrollingIRB Ready

Advanced Microsatellite Stable Colorectal Cancer Clinical Trial in Sioux Falls, SD

Access cutting-edge advanced microsatellite stable colorectal cancer treatment through this clinical trial at a research site in Sioux Falls. Study-provided care at no cost to qualified participants.

Sponsored by Gilead Sciences

Quick Self-Assessment

See if you qualify for this Sioux Falls location

Preparing your pre-screening questions…

Expert Care in Sioux Falls

Access advanced microsatellite stable colorectal cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related advanced microsatellite stable colorectal cancer treatment provided free

Apply for This Sioux Falls Location

Check if you qualify for this advanced microsatellite stable colorectal cancer clinical trial in Sioux Falls, SD

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Sioux Falls

    Convenient for SD residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Sioux Falls site if eligible
  4. 4Begin participation

About This Advanced Microsatellite Stable Colorectal Cancer Study in Sioux Falls

The goal of this clinical study is to learn more about the study drug, Denikitug (DEN, GS-1811), to evaluate the efficacy and safety of Denikitug Monotherapy and Denikitug-based Combinations in participants with advanced microsatellite stable (MSS) colorectal cancer (CRC). The primary objective of this study is to assess the effect of DEN as monotherapy and in combination with nivolumab (NIVO) or trifluridine-tipiracil (FTD-TPI) and bevacizumab (BVZ) on objective response rate (ORR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1).

Sponsor: Gilead Sciences

Who Can Participate

Inclusion Criteria

Medical History/Physical Characteristics
Histologically or cytologically confirmed unresectable, recurrent, or locally advanced or metastatic microsatellite stable colorectal cancer (MSS CRC) (adenocarcinoma, excluding appendix cancer).
Documented MSS or proficient mismatch repair (pMMR) disease by local assessment using a validated polymerase chain reaction (PCR) (microsatellite status) and/or immunohistochemistry (IHC) mismatch repair (MMR) assay is required.
Has received up to 2 prior lines of systemic therapy for advanced or metastatic CRC, which must have included at least fluoropyrimidine-, oxaliplatin-, irinotecan-based chemotherapies if indicated; and if applicable: anti-vascular endothelial growth factor (VEGF) therapy, anti epidermal growth factor receptor (EGFR) therapy, encorafenib or adagrasib/sotorasib.
Documented progressive disease (PD) by computed tomography (CT) or magnetic resonance imaging (MRI) during or after the most recent therapy per RECIST Version 1.1 criteria by investigator assessment.
Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1. Laboratory Assessments
Have adequate organ function. Key

Exclusion Criteria

with: Medical Conditions/History:
Significant cardiovascular disease.
History of autoimmune disease or active autoimmune disease that has required systemic treatment within 2 years.
History of (noninfectious) pneumonitis/interstitial lung disease or current pneumonitis/ interstitial lung disease.
History of gastrointestinal (GI) perforation, permanent ileostomy, abdominal abscess or fistula within 6 months, active or uncontrolled GI bleeding within 4 weeks, or any condition associated with significant risk of bleeding or perforation (eg, untreated varices, tumor erosion, recent GI surgery). Prior/Concurrent Therapy or Clinical Study Experience Prior treatment with:
Trifluridine-tipiracil, regorafenib, or fruquitinib.
Any immuno-oncology therapy.
Anticancer biologic agent within 4 weeks prior to randomization or have had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to randomization and have not recovered (ie, Grade 2 or less) from AEs from prior anticancer therapy at the time of randomization. Individuals in observational studies are eligible.
Allogeneic tissue/solid organ transplantation, including allogeneic stem cell transplantation. Exception: prior corneal transplant without requirement for systemic immunosuppressive agents is allowed. Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Sioux Falls?

Yes, this clinical trial (NCT07527858) has an active research site in Sioux Falls, SD that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced Microsatellite Stable Colorectal Cancer Treatment Options in Sioux Falls, SD

If you're searching for advanced microsatellite stable colorectal cancer treatment options in Sioux Falls, SD, this clinical trial (NCT07527858) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Sioux Falls research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced microsatellite stable colorectal cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced microsatellite stable colorectal cancer clinical trials near you to find additional studies recruiting in your area.

More Colorectal Cancer Trials in Sioux Falls, SD

See all colorectal cancer clinical trials recruiting in Sioux Falls — not just this study.

Browse Colorectal Cancer Trials in Sioux Falls →

Browse More Trials by Condition

Colorectal Cancer TrialsHeart Attack TrialsAlzheimers Disease TrialsSleep Apnea TrialsAtopic Dermatitis TrialsErectile Dysfunction TrialsInterstitial Cystitis TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Sioux Falls?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Sioux Falls, SD